Design of Glycopeptides Used to Investigate Class II MHC Binding and T-Cell Responses Associated with Autoimmune Arthritis
Open Access
- 15 March 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (3), e17881
- https://doi.org/10.1371/journal.pone.0017881
Abstract
The glycopeptide fragment CII259–273 from type II collagen (CII) binds to the murine Aq and human DR4 class II Major Histocompatibility Complex (MHC II) proteins, which are associated with development of murine collagen-induced arthritis (CIA) and rheumatoid arthritis (RA), respectively. It has been shown that CII259–273 can be used in therapeutic vaccination of CIA. This glycopeptide also elicits responses from T-cells obtained from RA patients, which indicates that it has an important role in RA as well. We now present a methodology for studies of (glyco)peptide-receptor interactions based on a combination of structure-based virtual screening, ligand-based statistical molecular design and biological evaluations. This methodology included the design of a CII259–273 glycopeptide library in which two anchor positions crucial for binding in pockets of Aq and DR4 were varied. Synthesis and biological evaluation of the designed glycopeptides provided novel structure-activity relationship (SAR) understanding of binding to Aq and DR4. Glycopeptides that retained high affinities for these MHC II proteins and induced strong responses in panels of T-cell hybridomas were also identified. An analysis of all the responses revealed groups of glycopeptides with different response patterns that are of high interest for vaccination studies in CIA. Moreover, the SAR understanding obtained in this study provides a platform for the design of second-generation glycopeptides with tuned MHC affinities and T-cell responses.Keywords
This publication has 79 references indexed in Scilit:
- T cell receptor signaling induced by an analog peptide of type II collagen requires activation of SykClinical Immunology, 2009
- Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263–275) epitope: an MHC anchor variant peptide for immune modulationArthritis Research & Therapy, 2007
- Exploration of the P6/P7 Region of the Peptide-binding Site of the Human Class II Major Histocompatability Complex Protein HLA-DR1Published by Elsevier BV ,2003
- LIGAND RECOGNITION BY αβ T CELL RECEPTORSAnnual Review of Immunology, 1998
- Design of MHC class II (DR4) ligands using conformationally restricted imino acids at p3 and p5Bioorganic & Medicinal Chemistry Letters, 1996
- A TCR Binds to Antagonist Ligands with Lower Affinities and Faster Dissociation Rates Than to AgonistsImmunity, 1996
- Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.Proceedings of the National Academy of Sciences of the United States of America, 1994
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987
- Immunisation against heterologous type II collagen induces arthritis in miceNature, 1980
- D-Optimality for Regression Designs: A ReviewTechnometrics, 1975